- Home
- / Leap Therapeutics
Leap Therapeutics
Stock Price
$4.6
2024-10-29
Market Capitalization
$176.4 M
2024-10-29
Leap Therapeutics Summary
Company Summary
- Overview
- Leap Therapeutics (also known as Cypherpunk Technologies, formerly known as HealthCare Pharmaceuticals) is a biopharmaceutical company developing targeted and immuno-oncology therapeutics. It offers DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 protein; FL-301, a humanized monoclonal antibody targeting Claudin18.2; and other antibody programs targeting Claudin18.2/CD137 and GDF15.
- Type
- Public
- Status
- Active
- Founded
- 2011
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://www.leaptx.com
- Cybersecurity rating
Table of Contents
Key People
Mark O'Mahony, Chief Manufacturing Officer
Gus Lawlor, Chief Operating Officer
Jason Baum, Chief Scientific Officer
LocationsView all
1 location detected
Cambridge, MA HQ
United States
47 Thorndike St B1-1
Leap Therapeutics Financials
Summary Financials
- Net income (Q1, 2026)
- ($77.2M)
- Cash (Q1, 2026)
- $6.7M
- EBIT (Q1, 2026)
- ($4.8M)
- Enterprise value
- $169.8M